Highlights and Quick Summary
- EBIT for the quarter ending June 30, 2023 was $-10.1 Million (a -8.81% decrease compared to previous quarter)
- Year-over-year quarterly EBIT increased by 371.44%
- Annual EBIT for 2022 was $-35.1 Million (a 2.36% increase from previous year)
- Annual EBIT for 2021 was $-34.3 Million (a 171.68% increase from previous year)
- Annual EBIT for 2020 was $-12.6 Million (a -36.75% decrease from previous year)
- Twelve month EBIT ending June 30, 2023 was $-34.7 Million (a -2.9% decrease compared to previous quarter)
- Twelve month trailing EBIT increased by 15.31% year-over-year
Trailing EBIT for the last four month:
| 30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
|---|---|---|---|
| $-34.7 Million | $-35.7 Million | $-35.1 Million | $-30.1 Million |
Visit stockrow.com/DRRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBIT of DURECT Corporation
Most recent EBITof DRRX including historical data for past 10 years.Interactive Chart of EBIT of DURECT Corporation
DURECT Corporation EBIT for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $-10.05 | $-11.02 | – | – | – |
| 2022 | $-11.5 | $-2.13 | $-11.09 | $-10.37 | $-35.08 |
| 2021 | $-6.51 | $-9.46 | $-8.66 | $-9.65 | $-34.27 |
| 2020 | $-8.31 | $-8.83 | $14.34 | $-9.82 | $-12.62 |
| 2019 | $-4.47 | $-1.71 | $-6.77 | $-6.71 | $-19.94 |
| 2018 | $-6.91 | $-2.29 | $-6.61 | $-7.83 | $-23.64 |
| 2017 | $8.57 | $6.13 | $-9.37 | $-7.57 | $-2.24 |
| 2016 | $-8.26 | $-8.29 | $-8.5 | $-7.32 | $-32.36 |
| 2015 | $-5.33 | $-5.97 | $-4.94 | $-4.42 | $-20.66 |
| 2014 | $-5.36 | $-6.59 | $-5.45 | $-3.6 | $-21.0 |
| 2013 | $-5.09 | $-5.72 | $-5.16 | $-5.2 | $-21.16 |
| 2012 | $-5.59 | $-4.81 | – | – | $16.06 |
Business Profile of DURECT Corporation
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic